Sarepta Therapeutics Inc.’s stock has declined by 23% following the death of a patient who used its gene therapy Elevidys for Duchenne muscular dystrophy, citing liver failure as a known possible side effect. However, this is the first reported case of such an outcome.
Analysts are weighing in on the market’s response to the event, with some suggesting that the sell-off may be overdone given the risks associated with the treatment. This highlights the need for careful consideration and transparency from biotech companies when it comes to reporting side effects.
The incident has raised concerns about the safety profile of Elevidys, which remains the only approved treatment for DMD. As the company continues to monitor patient outcomes, investors will be watching closely to assess whether the benefits of the therapy outweigh its risks.
Source: https://www.marketwatch.com/story/sarepta-therapeutics-stock-falls-after-dmm-patient-dies-of-liver-failure-1ba83398